Drugs In The Making
  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact

Drug Research Updates

Post Title.

1/18/2010

0 Comments

 
Sanofi fails to win preliminary NICE backing for its Multaq heart drug.
Sanofi-Aventis SA failed to win the preliminary backing of the UK's health-cost panel for its Multaq [dronedarone] heart medicine after a committee said the medicine isn't more beneficial than standard therapies." The UK's "National Institute for Health and Clinical Excellence's [NICE] independent appraisal committee found that the drug doesn't work as well and costs more than medicines already on the market, NICE said today in an emailed statement and added that "NICE will make a final recommendation on whether the UK's National Health Service should pay for the medicine after a consultation period that ends on Jan. 28 2010.  

MedImmune responds to FDA inquiry regarding motavizumab. AstraZeneca PLC, the London pharmaceutical that owns MedImmune, said the local subsidiary has filed its formal responses to the Food and Drug Administration's questions about motavizumab, an enhanced version of MedImmune's blockbuster drug Synagis." According to the Business Journal, the drug, which treats respiratory syncytial virus disease in infants, "has hit its share of delays to market."  


Combination therapy with mirtazapine may be more effective than fluoxetine alone.
According to a study published online Dec. 15 in the American Journal of Psychiatry, "mirtazapine used in combination with fluoxetine, venlafaxine, or bupropion is more effective and as well tolerated in treating major depressive disorder (MDD) as fluoxetine alone." After treating "a total of 105 patients meeting Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for MDD," researchers found that "patients treated with these combinations had mean differences of 4.5 to 4.8 points on the Hamilton Depression Rating Scale (HAM-D) by day 42, compared with those treated with monotherapy." 
 
FDA says Aridol cannot be approved in present form.
Pharmaxis, Ltd. reported that it has received a so-called complete response letter from the US Food and Drug Administration saying the application for its lung-function test Aridol [mannitol dry powder for inhalation] couldn't be approved in the present form." The agency "cited deficiencies at three manufacturing and testing subcontractors, a labeling issue, and post-marketing requirements, Pharmaxis said in a statement." The company plans to "address the issues and seek approval as soon as possible," Pharmaxis CEO Alan Robertson said. Aridol, which is already "approved for sale in Australia, major European countries, and Korea," is "a lung function test designed to help doctors diagnose and manage asthma by detecting active airway inflammation through measuring airway hyper-responsiveness."  

Monoclonal antibody may be promising in Ewing's sarcoma.
A monoclonal antibody that targets an insulin-like growth-factor receptor (IGF-1R) was well tolerated and demonstrated antitumor activity in refractory Ewing's sarcoma," according to research appearing online in Lancet Oncology. In a study of "29 patients with advanced sarcomas treated with figitumumab," researchers assessed "tumor response...every six to eight weeks by CT, MRI, or both." The study showed that "two patients...had confirmed responses," and eight "had disease stabilization." Researchers found "no cardiac toxicity," and "no substantial change in cardiac valve function or left ventricular ejection fraction," which they said "was noteworthy...because IGF-1R is expressed on cardiac myocytes, and three-quarters of the patients had previously received potentially cardiotoxic anthracyclines."  

Patients with MDD taking paroxetine may undergo greater personality change.
According to a study published in the Dec. issue of the Archives of General Psychiatry, "patients with major depressive disorder (MDD) taking paroxetine underwent greater personality change than those taking placebo, including a significant reduction in neuroticism and a marked increase in extraversion, even after controlling for depression improvement." Researchers arrived at that conclusion after randomizing "240 MDD patients aged 18 to 70 years to receive paroxetine (n = 120), placebo (n = 60), or cognitive therapy (n = 60)," then following them for a year. Notably, paroxetine "appears to have a positive effect on personality that is separate and distinct from its antidepressant effects."  

Also at http://www.pharm-education.com/2010/01/drug-clinical-research-updates_18.html 

Disclaimer : The information presented here is for knowledge purpose only and should not be interpreted as medical advise.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    shruti bhat, pharmaceutical manufacturing and continuous improvement expert
    Dr. Shruti Bhat

    Pharmaceutical Manufacturing, Continuous Improvement and Business Transformation Consultant


    Picture

    how to choose business process improvement methodology
    18 business process improvement methodologies, shruti bhat

    Categories

    All
    Drug Research Updates


      Contact

    SEND
Disclaimer:

The website, blog information, audios, videos, white papers and all other associated published content on this website is the sole property of Innoworks, Canada and is under Copy Right protection. Not to be copied, distributed or used without prior authorization of the owner. The blog provides information for general knowledge sharing for community benefit and is for academic purpose only. Please give courtesy credits to respective authors in case information published here is used as a reference.
 
Additionally, information published on the blog, resource library etc. should not be considered or construed as legal and/or medical advice.  For diagnosis of an ailment, it is recommended that one seeks help of a registered medical practitioner, while medicines should be received from a registered pharmacist only. Seek advise of registered legal expert for any information pertaining law(s).

 The authors and website owner have used their best efforts in preparing this site. The information contained herein has been stated accurately to the best ability of the authors. The information contained herein is strictly for educational purposes. The author and website owner make no representation or warranties with respect to the accuracy, contrary interpretations of the subject matter herein, applicability, fitness or completeness of the contents. Therefore, if you wish to apply ideas contained on this website, you are taking full responsibility for your actions. The author and website owner specifically disclaim any liability that is incurred from the use or application of the contents sated here.

Please note that by continuing to read this site, you agree that you have read and understood this disclaimer and are continuing to read or utilize information from this site at your own responsibility and risk. Under no circumstances can you hold us responsible for any outcome or result from your having read or followed any of the expressions/suggestions/recommendations from this site.  We hope you expand your understanding and that many of the ideas and suggestions provided on this site help you. BUT we do not take on any implicit or explicit liability for anyone following any of those suggestions, ideas or advices. This is also applicable for any comments and discussions being carried out on this site.
 
For queries regarding any posted content, please feel free to contact the web administrator using contact form.
Terms & Conditions of site usage

©
2001- 2017 Copyrighted content, ALL RIGHTS RESERVED.


  • Shruti's Blog
  • About Shruti Bhat
  • QUALITY BLOG
  • Industry News
  • Free Ebook
  • Research Updates
    • Drug Research
    • Clinical Research
  • Contact